MedTrace Logo

Vancomycin-Associated Nephrotoxicity

NCT01216540 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 398

Last updated 2022-10-03

No results posted yet for this study

Summary

The primary goal of this study is to determine if there is an association between greater exposure to vancomycin and the development of nephrotoxicity. The secondary goal is to estimate the costs to the hospital associated with these nephrotoxic events.

Conditions

  • Nephrotoxicity

Sponsors & Collaborators

  • Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

    collaborator INDUSTRY

  • University at Buffalo

    lead OTHER

Principal Investigators

  • Jack Brown, PharmD · State University of New York at Buffalo

  • Vanessa Stevens, PhD · Internal Medicine, Division of Epidemiology, University of Utah School of Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2011-04-30
Completion
2011-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01216540 on ClinicalTrials.gov